Quince Therapeutics (NASDAQ:QNCX – Get Rating) and AVROBIO (NASDAQ:AVRO – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.
Insider & Institutional Ownership
31.1% of Quince Therapeutics shares are held by institutional investors. Comparatively, 65.0% of AVROBIO shares are held by institutional investors. 27.9% of Quince Therapeutics shares are held by insiders. Comparatively, 9.2% of AVROBIO shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Quince Therapeutics and AVROBIO’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Quince Therapeutics | N/A | -41.56% | -39.80% |
| AVROBIO | N/A | -117.18% | -87.33% |
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Quince Therapeutics | N/A | N/A | -$51.66 million | ($2.23) | -0.69 |
| AVROBIO | N/A | N/A | -$105.89 million | ($2.30) | -0.40 |
Quince Therapeutics is trading at a lower price-to-earnings ratio than AVROBIO, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent recommendations and price targets for Quince Therapeutics and AVROBIO, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Quince Therapeutics | 0 | 0 | 0 | 0 | N/A |
| AVROBIO | 0 | 0 | 2 | 0 | 3.00 |
AVROBIO has a consensus price target of $5.00, suggesting a potential upside of 443.36%. Given AVROBIO’s higher possible upside, analysts plainly believe AVROBIO is more favorable than Quince Therapeutics.
Risk & Volatility
Quince Therapeutics has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, AVROBIO has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500.
About Quince Therapeutics
Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. Its pipeline consists of COR388, COR588, COR788, COR822, and Coronavirus 3CL protease inhibitor. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.
About AVROBIO
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm’s clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Cambridge, MA.
Receive News & Ratings for Quince Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quince Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
